Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Insider Terrie Curran Buys 20,500 Shares

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Get Rating) insider Terrie Curran purchased 20,500 shares of the business’s stock in a transaction dated Friday, May 13th. The shares were purchased at an average price of $7.41 per share, for a total transaction of $151,905.00. Following the acquisition, the insider now directly owns 64,595 shares of the company’s stock, valued at $478,648.95. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

PHAT stock opened at $8.19 on Tuesday. Phathom Pharmaceuticals, Inc. has a 52-week low of $6.74 and a 52-week high of $39.02. The company’s 50 day simple moving average is $13.17 and its 200-day simple moving average is $16.71. The company has a debt-to-equity ratio of 2.39, a current ratio of 12.79 and a quick ratio of 9.86. The firm has a market capitalization of $259.73 million, a P/E ratio of -2.05 and a beta of 0.93.

Phathom Pharmaceuticals (NASDAQ:PHAT – Get Rating) last announced its quarterly earnings data on Tuesday, March 1st. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.09). Sell-side analysts predict that Phathom Pharmaceuticals, Inc. will post -4.03 EPS for the current fiscal year.

Separately, Zacks Investment Research lowered shares of Phathom Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Royal Bank of Canada grew its position in Phathom Pharmaceuticals by 34.7% during the third quarter. Royal Bank of Canada now owns 1,868 shares of the company’s stock valued at $60,000 after purchasing an additional 481 shares in the last quarter. Deutsche Bank AG grew its position in Phathom Pharmaceuticals by 5.3% during the fourth quarter. Deutsche Bank AG now owns 12,839 shares of the company’s stock valued at $253,000 after purchasing an additional 642 shares in the last quarter. Exane Derivatives grew its position in Phathom Pharmaceuticals by 16.1% during the first quarter. Exane Derivatives now owns 5,874 shares of the company’s stock valued at $80,000 after purchasing an additional 816 shares in the last quarter. Advisor Group Holdings Inc. grew its position in Phathom Pharmaceuticals by 69.7% during the third quarter. Advisor Group Holdings Inc. now owns 2,076 shares of the company’s stock valued at $67,000 after purchasing an additional 853 shares in the last quarter. Finally, Northern Trust Corp grew its position in Phathom Pharmaceuticals by 1.0% during the fourth quarter. Northern Trust Corp now owns 187,905 shares of the company’s stock valued at $3,696,000 after purchasing an additional 1,829 shares in the last quarter. 90.11% of the stock is currently owned by hedge funds and other institutional investors.

About Phathom Pharmaceuticals (Get Rating)

Phathom Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.

Recommended Stories